Harvard Bioscience Stock Performance

HBIO Stock  USD 0.59  0.01  1.67%   
The company retains a Market Volatility (i.e., Beta) of 2.31, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Harvard Bioscience will likely underperform. Harvard Bioscience right now retains a risk of 5.04%. Please check out Harvard Bioscience value at risk, as well as the relationship between the skewness and day median price , to decide if Harvard Bioscience will be following its current trending patterns.

Risk-Adjusted Performance

Soft

 
Weak
 
Strong
Over the last 90 days Harvard Bioscience has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, Harvard Bioscience is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
Last Split Factor
1319:1000
Last Split Date
2013-11-04
1
How Harvard Bioscience Inc. stock compares with tech leaders - July 2025 News Drivers High Conviction Buy Zone Picks - newser.com
11/19/2025
2
Market Catalysts How Harvard Bioscience Inc. stock responds to job market shifts - Weekly Trade Report Reliable Trade Execution Plans - ulpravda.ru
01/08/2026
3
Harvard Bioscience Lowers Quorum Requirement for Shareholders - TipRanks
01/20/2026
4
Acquisition by Cote Jennifer of 35800 shares of Harvard Bioscience subject to Rule 16b-3
01/26/2026
5
Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth
01/29/2026
6
Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 Outlines Long-Term Strategic Focus Areas
02/10/2026
Begin Period Cash Flow4.3 M
Total Cashflows From Investing Activities-1.3 M

Harvard Bioscience Relative Risk vs. Return Landscape

If you would invest  63.00  in Harvard Bioscience on November 21, 2025 and sell it today you would lose (4.00) from holding Harvard Bioscience or give up 6.35% of portfolio value over 90 days. Harvard Bioscience is currently generating 0.0104% in daily expected returns and assumes 5.0386% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Harvard, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Harvard Bioscience is expected to generate 11.88 times less return on investment than the market. In addition to that, the company is 6.74 times more volatile than its market benchmark. It trades about 0.0 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.17 per unit of volatility.

Harvard Bioscience Target Price Odds to finish over Current Price

The tendency of Harvard Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.59 90 days 0.59 
about 72.32
Based on a normal probability distribution, the odds of Harvard Bioscience to move above the current price in 90 days from now is about 72.32 (This Harvard Bioscience probability density function shows the probability of Harvard Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.31 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Harvard Bioscience will likely underperform. Additionally Harvard Bioscience has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Harvard Bioscience Price Density   
       Price  

Predictive Modules for Harvard Bioscience

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Harvard Bioscience. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.030.585.83
Details
Intrinsic
Valuation
LowRealHigh
0.050.926.17
Details
Naive
Forecast
LowNextHigh
0.010.645.89
Details
2 Analysts
Consensus
LowTargetHigh
1.822.002.22
Details

Harvard Bioscience Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Harvard Bioscience is not an exception. The market had few large corrections towards the Harvard Bioscience's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Harvard Bioscience, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Harvard Bioscience within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.02
β
Beta against Dow Jones2.31
σ
Overall volatility
0.08
Ir
Information ratio 0

Harvard Bioscience Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Harvard Bioscience for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Harvard Bioscience can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Harvard Bioscience had very high historical volatility over the last 90 days
Harvard Bioscience has some characteristics of a very speculative penny stock
Harvard Bioscience has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 94.14 M. Net Loss for the year was (12.4 M) with profit before overhead, payroll, taxes, and interest of 49.79 M.
Latest headline from globenewswire.com: Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 Outlines Long-Term Strategic Focus Areas

Harvard Bioscience Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Harvard Stock often depends not only on the future outlook of the current and potential Harvard Bioscience's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Harvard Bioscience's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding43.5 M
Cash And Short Term Investments4.1 M

Harvard Bioscience Fundamentals Growth

Harvard Stock prices reflect investors' perceptions of the future prospects and financial health of Harvard Bioscience, and Harvard Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Harvard Stock performance.

About Harvard Bioscience Performance

By examining Harvard Bioscience's fundamental ratios, stakeholders can obtain critical insights into Harvard Bioscience's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Harvard Bioscience is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 193.96  112.96 
Return On Tangible Assets(0.19)(0.20)
Return On Capital Employed(0.10)(0.09)
Return On Assets(0.09)(0.09)
Return On Equity(0.18)(0.19)

Things to note about Harvard Bioscience performance evaluation

Checking the ongoing alerts about Harvard Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Harvard Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Harvard Bioscience had very high historical volatility over the last 90 days
Harvard Bioscience has some characteristics of a very speculative penny stock
Harvard Bioscience has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 94.14 M. Net Loss for the year was (12.4 M) with profit before overhead, payroll, taxes, and interest of 49.79 M.
Latest headline from globenewswire.com: Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 Outlines Long-Term Strategic Focus Areas
Evaluating Harvard Bioscience's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Harvard Bioscience's stock performance include:
  • Analyzing Harvard Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Harvard Bioscience's stock is overvalued or undervalued compared to its peers.
  • Examining Harvard Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Harvard Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Harvard Bioscience's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Harvard Bioscience's stock. These opinions can provide insight into Harvard Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Harvard Bioscience's stock performance is not an exact science, and many factors can impact Harvard Bioscience's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Harvard Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Harvard Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Harvard Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Harvard Bioscience Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Will Life Sciences Tools & Services sector continue expanding? Could Harvard diversify its offerings? Factors like these will boost the valuation of Harvard Bioscience. Market participants price Harvard higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Harvard Bioscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
(0.80)
Earnings Share
(1.20)
Revenue Per Share
1.979
Quarterly Revenue Growth
(0.06)
Return On Assets
(0.01)
Harvard Bioscience's market price often diverges from its book value, the accounting figure shown on Harvard's balance sheet. Smart investors calculate Harvard Bioscience's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Harvard Bioscience's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.